DE3783588D1 - Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren. - Google Patents

Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren.

Info

Publication number
DE3783588D1
DE3783588D1 DE8787902737T DE3783588T DE3783588D1 DE 3783588 D1 DE3783588 D1 DE 3783588D1 DE 8787902737 T DE8787902737 T DE 8787902737T DE 3783588 T DE3783588 T DE 3783588T DE 3783588 D1 DE3783588 D1 DE 3783588D1
Authority
DE
Germany
Prior art keywords
connections
new
production method
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787902737T
Other languages
English (en)
Other versions
DE3783588T2 (de
Inventor
Hirofumi Nakano
Isami Takahashi
Michio Ichimura
Isao Kawamoto
Kozo Asano
Fusao Tomita
Hiroshi Sano
Toru Yasuzawa
Makoto Morimoto
Kazuhisa Fujimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of DE3783588D1 publication Critical patent/DE3783588D1/de
Application granted granted Critical
Publication of DE3783588T2 publication Critical patent/DE3783588T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8787902737T 1986-04-17 1987-04-17 Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren. Expired - Lifetime DE3783588T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8903186 1986-04-17
JP9564986 1986-04-24
PCT/JP1987/000247 WO1987006265A1 (en) 1986-04-17 1987-04-17 Novel compounds dc-88a and dc-89a1 and process for their preparation

Publications (2)

Publication Number Publication Date
DE3783588D1 true DE3783588D1 (de) 1993-02-25
DE3783588T2 DE3783588T2 (de) 1993-06-09

Family

ID=26430476

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787902737T Expired - Lifetime DE3783588T2 (de) 1986-04-17 1987-04-17 Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren.

Country Status (5)

Country Link
US (1) US4923990A (de)
EP (1) EP0271581B1 (de)
JP (1) JPH0684377B1 (de)
DE (1) DE3783588T2 (de)
WO (1) WO1987006265A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994578A (en) * 1987-11-27 1991-02-19 Meiji Seika Kaisha, Ltd. Certain anti-tumor duocarmycin antibiotics from streptomyces
EP0318056A3 (de) * 1987-11-27 1990-12-19 Meiji Seika Kaisha Ltd. Antibiotika und Verfahren zu deren Herstellung
JP2642165B2 (ja) * 1988-07-22 1997-08-20 協和醗酵工業株式会社 新規ｄｃ−８９化合物およびその製造法
US5084468A (en) * 1988-08-11 1992-01-28 Kyowa Hakko Kogyo Co., Ltd. Dc-88a derivatives
US5008271A (en) * 1988-10-21 1991-04-16 Kyowa Hakko Kogyo Co., Ltd. DC-88A derivatives
JP2598116B2 (ja) * 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5187186A (en) * 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) * 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5248692A (en) * 1990-06-11 1993-09-28 Kyowa Hakko Kogyo Co., Ltd. DC-89 derivatives as anti-tumor agents
US5214065A (en) * 1990-06-11 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
DE69121334T2 (de) * 1990-07-26 1997-03-20 Kyowa Hakko Kogyo Kk DC-89-Derivate als Antitumor-Wirkstoffe
EP0520435A3 (en) * 1991-06-28 1993-05-05 Kyowa Hakko Kogyo Co., Ltd. Dc-89 derivatives
JPH05279374A (ja) * 1992-03-31 1993-10-26 Sawao Murao スイダトレスチン及びその製造方法
US20040136908A1 (en) * 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
EP1434778A4 (de) * 2001-05-31 2005-07-13 Medarex Inc Cytotoxine und prodrugs, linker und stabilisatoren dafür
NZ550934A (en) * 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
JP5651285B2 (ja) 2005-02-15 2015-01-07 デューク ユニバーシティ 抗ｃｄ１９抗体および腫瘍学における使用
KR20070115967A (ko) * 2005-02-18 2007-12-06 메다렉스, 인코포레이티드 전립선 특이 막 항원(ｐｓｍａ)에 대한 인간 모노클로날항체
EP2384767B1 (de) 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. OV064-bindende Antikörper und Verfahren zu deren Verwendung
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP1885755A4 (de) 2005-05-05 2009-07-29 Univ Duke Cd19-antikörper-therapie für autoimmunerkrankungen
CA2623652C (en) * 2005-09-26 2013-11-26 Medarex, Inc. Antibody-drug conjugates and methods of use
AU2006305842B2 (en) 2005-10-26 2011-11-03 E. R. Squibb & Sons, L.L.C. Methods and compounds for preparing CC-1065 analogs
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP2540741A1 (de) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
CA2678514A1 (en) * 2007-02-21 2008-08-28 Medarex, Inc. Chemical linkers with single amino acids and conjugates thereof
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
EP2927244A1 (de) 2008-09-19 2015-10-07 MedImmune, LLC Gegen DLL4 gerichtete Antikörper und ihre Verwendung
ES2719496T3 (es) 2008-11-12 2019-07-10 Medimmune Llc Formulación de anticuerpo
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
TWI529247B (zh) 2009-05-13 2016-04-11 建新公司 抗人類ｃｄ５２免疫球蛋白
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
ES2646863T3 (es) 2009-11-24 2017-12-18 Medimmune Limited Agentes de unión específica contra B7-H1
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
EP3828205A1 (de) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1-antikörper
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
DK2766392T3 (da) 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
EP3620473A1 (de) 2013-01-14 2020-03-11 Xencor, Inc. Neuartige heterodimere proteine
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
AU2014207549B2 (en) 2013-01-15 2018-12-06 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CA2902739C (en) 2013-03-15 2022-11-22 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CR20160156A (es) 2013-10-11 2016-11-01 Oxford Biotherapeutics Ltd Anticuerpos conjugados contra ly75 para el tratamiento del cáncer
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
ME03666B (de) 2014-03-28 2020-10-20 Xencor Inc Bispezifische, an cd38 und cd3 bindende antikörper
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
WO2016014984A1 (en) 2014-07-24 2016-01-28 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3223845B1 (de) 2014-11-26 2021-05-19 Xencor, Inc. Cheterodimere antikörper zur bindung von cd3 und cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
KR20170084327A (ko) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Cd3 및 cd38에 결합하는 이형이량체 항체
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
RU2022104399A (ru) 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102562519B1 (ko) 2016-10-14 2023-08-02 젠코어 인코포레이티드 IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
US20210308277A1 (en) 2016-11-14 2021-10-07 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
JOP20200343A1 (ar) 2018-07-02 2020-12-31 Xencor Inc بروتين ربط مولد ضد مضاد لـ steap1
CA3115096A1 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169888A (en) * 1977-10-17 1979-10-02 The Upjohn Company Composition of matter and process
JPS5774090A (en) * 1980-10-27 1982-05-10 Shionogi & Co Ltd Novel beta-galactosidase inhibitor, gt-2558, its derivative, and production
US4423229A (en) * 1980-11-18 1983-12-27 The Upjohn Company Composition of matter and process
US4413132A (en) * 1980-11-18 1983-11-01 The Upjohn Company Antibiotic CC-1065 indoline intermediates
US4400518A (en) * 1980-11-18 1983-08-23 The Upjohn Company Composition of matter and process
US4423230A (en) * 1980-11-18 1983-12-27 The Upjohn Company Preparation of an intermediate for N-(methylsulfonyl)-1,2,8,8a-cyclopropa[c][1,2-b:-4,3-b']dipyrol-4(5H)-one
US4423228A (en) * 1980-11-18 1983-12-27 The Upjohn Company Process for preparing N-(methyl-sulfonyl)-1,2,8,8a-cyclopropa[c]benzo[1,2-b:4,3-b']dipyrrol-4(5H)-one
CA1238907A (en) * 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
AU617304B2 (en) * 1986-12-19 1991-11-28 Pharmacia & Upjohn Company Novel cc-1065 analogs

Also Published As

Publication number Publication date
JPH0684377B1 (de) 1994-10-26
DE3783588T2 (de) 1993-06-09
EP0271581B1 (de) 1993-01-13
EP0271581A4 (de) 1989-06-26
EP0271581A1 (de) 1988-06-22
US4923990A (en) 1990-05-08
WO1987006265A1 (en) 1987-10-22

Similar Documents

Publication Publication Date Title
DE3783588D1 (de) Neue verbindungen dc-88a und dc-89a1 und deren herstellungsverfahren.
DE3778944D1 (de) Dreidimensionale integrierte schaltung und deren herstellungsverfahren.
DE3780302T2 (de) Herstellungsverfahren und -apparat.
DE3772721D1 (de) Profilstueck und herstellungsverfahren.
DE3581059D1 (de) Halosilan-katalysator und dessen herstellungsverfahren.
DE3771487D1 (de) Dekorative schichtpressstoffplatte und verfahren zu deren herstellung.
DE3772619D1 (de) Mischverfahren.
DE3670803D1 (de) Neue verbindungen und neue aufzeichnungsmaterialien, die diese verwenden.
DE3782952T2 (de) Supraleitende dipolmagnete und verfahren zu deren herstellung.
DE3777141D1 (de) Mikrokapseln und verfahren zur herstelllung.
DE3777618D1 (de) Elektroabscheidungsverfahren und waesserige harz-lackzusammensetzung.
DE68902670T2 (de) Ks-506 verbindungen und verfahren zu deren herstellung.
DE3861709D1 (de) Anti-hiv-mittel und methode zu deren erzeugung.
DE3582584D1 (de) 2-piperazinopyrimidinabkoemmlinge und deren herstellung.
DE3668366D1 (de) Manschettenverbindung und deren herstellungsverfahren.
DE3679739D1 (de) Dekorative fassung und verfahren zu deren herstellung.
DE3483314D1 (de) 7-fluorprostaglandine und deren herstellungsverfahren.
DE3687377D1 (de) Vitamin-d-abkoemmlinge und deren herstellungsverfahren.
DE3788389T2 (de) Cervinomycinabkömmlinge als antibiotika und deren herstellungsverfahren.
DE3687576T2 (de) Bauelement und herstellungsverfahren.
DE3783670T2 (de) Neue verbindungen und ihre anwendung.
DE3686266T2 (de) Neue 5-fluoruridin-verbindungen und deren herstellung.
DE3774950D1 (de) Harzartige festkoerperteilchen und deren herstellung.
DE3786795D1 (de) Antibiotikum yi-hu3 und herstellungsverfahren.
DE3776429D1 (de) Regalstruktur und deren herstellungsverfahren.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition